bioRxivPharmacology & ToxicologyPreprint
Restoring neurovascular coupling in Alzheimer's disease tauopathy through M1 mAChR modulation
Wesam BassiouniiD, Moahmed Abdelnaby, En-Hung AiiD, Khaled S. Abd‐ElrahmaniD
Abstract
Alzheimer's disease is characterized by progressive cognitive decline and early cerebrovascular dysfunction, including impaired neurovascular coupling (NVC) and reduced cerebral blood flow (CBF). Tau pathology is a major driver of these deficits, yet therapeutic strategies targeting tau-induced neurovascular dysfunction remain limited. The M1 muscarinic acetylcholine receptor (M1 mAChR) is a promising therapeutic target because of its critical role in cognition. We previously demonstrated that pharmacological activation of M1 mAChR improves cognitive function and neuronal survival in amyloid-based Alzheimer's disease mouse models through sex-specific mechanisms. However, whether M1 mAChR activation restores tau-mediated NVC deficits remains unknown. P301S mice were used as a model of tauopathy. Cognitive function was evaluated using the novel object recognition and Morris water maze tests, and NVC was assessed by measuring whisker stimulation-induced changes in CBF using laser speckle contrast imaging. Following baseline measurements, mice received an acute intraperitoneal injection of VU0486846, a selective M1 mAChR positive allosteric modulator (3 mg/kg), and CBF responses were reassessed over time. P301S tau mice exhibited impaired recognition and spatial memory functions, associated with reduced whisker stimulation-induced increase in CBF, indicative of impaired NVC response, while acute treatment with VU0486846 reversed these changes in NVC. This rescuing effect of VU0486846 was observed earlier in female tau mice compared to males, suggesting a sex-biased effect of M1 mAChR modulation. These findings demonstrate that M1 mAChR positive allosteric modulation reverses tau-induced neurovascular dysfunction, supporting M1 mAChR activation as a promising disease-modifying approach for Alzheimer's disease. The earlier improvement observed in females further suggests that therapeutic efficacy is influenced by biological sex.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- mTOR drives cerebrovascular dysfunction and blood-brain barrier breakdown in a model of Alzheimers disease with cerebral amyloid angiopathy
Candice E. Van Skike, Lauren R. Miller, … Verónica Galván·bioRxiv·Sep 7, 2026
- Long-term Locus Coeruleus Stimulation Exacerbates Tau Pathology in PS19 Mice
Yuhan Nong, Steven M. Wellman, … Qi Wang·Journal of Alzheimer s DiseasePeer-reviewed·Jul 20, 2026
- p75 neurotrophin receptor signaling through the RhoA/ROCK pathway contributes to Alzheimers Disease tauopathy
Kang Liao, Meng Xie, Carlos F. Ibáñez·bioRxiv·Feb 23, 2026
- Chemogenetic activation of midline thalamic nuclei fails to ameliorate memory deficits in two mouse models of Alzheimer's disease
Shivali Kohli, Lilya Andrianova, … Michael T. Craig·bioRxiv·Jun 30, 2021
- Pharmacological potentiation of Nav1.1 channels in interneurons mitigates tau depositions and neuronal death in a mouse model of neurodegenerative dementias
Kazuaki Sampei, Junya Hirokawa, … Masafumi Shimojo·bioRxiv·Aug 20, 2025
- Sex-divergent trajectories of hippocampal and cortical NMDA receptor density across the Alzheimer 's disease continuum
Maricedes Acosta‐Martínez, Vanessa Carter, … Anat R Biegon·bioRxiv·Aug 7, 2026